Guardant Health, INC Form 4 insider transactions

Guardant Health Director Tariq Musa reported the sale of 3,213 shares of common stock and the acquisition of 6,833 stock options and 4,203 restricted stock units, all executed under a Rule 10b5-1 trading plan.

Myrtle S. Potter, a Director at Guardant Health, Inc., reported the sale of a small number of common shares and the acquisition of substantial stock options and restricted stock units, all executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Roberto Mignone was granted 6,833 stock options and 4,203 restricted stock units, aligning his interests with long-term shareholder value.

Guardant Health, Inc. Director Steve E. Krognes was granted 6,833 stock options and 4,203 restricted stock units (RSUs) as part of his compensation.

Guardant Health, Inc. Director Meghan V. Joyce was granted 6,833 stock options and 4,203 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

Guardant Health, Inc. Director Manuel Hidalgo Medina was granted 6,833 stock options and 4,203 restricted stock units on June 18, 2025, as part of his compensation.

Guardant Health, Inc. Director Vijaya Gadde has reported the acquisition of stock options and restricted stock units, granted on June 18, 2025, as part of her compensation.

Guardant Health, Inc. Director Ian T. Clark disclosed the sale of common stock and the acquisition of new stock options and restricted stock units, as part of pre-arranged trading plans.

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of common stock through RSU vesting and a concurrent sale for tax obligations, executed under a pre-arranged 10b5-1 plan.

Guardant Health, Inc.'s Chief Information Officer, Kumud Kalia, reported the acquisition of common stock through the vesting of restricted stock units, with a portion subsequently sold to cover tax withholding obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations, alongside an Employee Stock Purchase Plan acquisition.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, resulting in a net increase in his direct beneficial ownership.

Guardant Health's Chief Financial Officer, Michael Brian Bell, reported the scheduled vesting of Restricted Stock Units and subsequent tax-related share withholding on June 15, 2025, under a Rule 10b5-1 plan.

Myrtle S. Potter, a director at Guardant Health, Inc., reported the acquisition of common stock through Restricted Stock Unit (RSU) vesting and a subsequent sale of shares.

Guardant Health, Inc. Director Meghan V. Joyce acquired 6,674 shares through RSU vesting and subsequently sold 3,337 shares for $47.22 each, all under a Rule 10b5-1 trading plan.

Guardant Health Director Tariq Musa has reported the acquisition of 6,924 shares of common stock through the conversion of Restricted Stock Units (RSUs) in two separate transactions in mid-June 2025, increasing his direct beneficial ownership to 10,403 shares.

Guardant Health, Inc. Director Steve Krognes has acquired 6,674 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 17,665 shares.

Guardant Health, Inc. Director Vijaya Gadde has increased her beneficial ownership of common stock by 6,674 shares through the vesting of Restricted Stock Units.

Guardant Health Director Ian T. Clark reported the acquisition of 8,088 shares of common stock through the conversion of restricted stock units, increasing his indirect beneficial ownership.

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, sold 119,284 shares of common stock for approximately $5.97 million in early June 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Meghan V. Joyce reported the scheduled acquisition of 67 shares of common stock through the vesting of restricted stock units on June 4, 2025.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the sale of 4,000 shares of common stock for approximately $185,561 on June 3, 2025.

Guardant Health Director Meghan V. Joyce reported the sale of 100 shares of common stock at $41.66 per share, executed under a Rule 10b5-1 trading plan.

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of 263 common shares through RSU vesting and the disposition of 138 shares for tax withholding purposes.

Guardant Health's Chief Information Officer, Kumud Kalia, reported standard equity transactions including the vesting of Restricted Stock Units and participation in the Employee Stock Purchase Plan, alongside a disposition of shares for tax withholding.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the acquisition of common stock through RSU vesting and subsequent sale of shares to cover tax obligations, alongside an Employee Stock Purchase Plan acquisition.

Guardant Health, Inc. Director Steve E. Krognes reported the acquisition of 154 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 10,991 shares.

Director Tariq Musa reported selling 116 shares of Guardant Health, Inc. common stock at $40.04 per share on May 19, 2025.

Director Tariq Musa reports the vesting and conversion of restricted stock units into common stock.

Director Myrtle S. Potter reports a transaction involving Guardant Health, Inc. common stock on May 15, 2025.